Allison Morgan, BSc, has almost 30 years’ clinical development experience within the biopharmaceutical industry from the translational phase to First in Man to Registration programmes and beyond. Allison has held senior management positions to Vice President level for multi-national pharmaceutical companies, small biotechs and CROs, in Europe and the US. In her last position of VP Clinical R&D for Prosensa, Allison worked closely with the academic community and key regulatory agencies, developing novel outcome measures and advanced translational programme designs, regularly preparing for and attending Scientific Advice meetings. Although Allison has a particular expertise in paediatrics, rare and niche diseases such as genetic neuromuscular diseases, metabolic disorders and childhood cancers, she also has extensive experience in more traditional programmes ranging from anti-infectives to cardiovascular to autoimmune diseases. Projects have included therapeutic modalities such as RNA modulation as well as monoclonals and small molecules. Since starting consulting five years ago, Allison has supported numerous small and mid-size companies develop their clinical pathway through her creative thinking and expertise, supporting a variety of activities from due diligence to study design to clinical regulatory pathway and exit strategy.